The USFDA has approved pivmecillinam, a penicillin-type antibiotic for treating female adult patients with uncomplicated urinary tract infections (UTIs) caused by Escherichia coli , Staphylococcus saprophyticus , and Proteus mirabilis . Clinical evidence The safety and efficacy of pivmecillinam were evaluated in three controlled clinical trials comparing pivmecillinam to a placebo, another oral antibacterial drug, and ibuprofen.
Pivmecillinam achieved a composite response in more patients than in the placebo and ibuprofen groups (Table 1). Table 1 : Comparing pivmecillinam to a placebo, an oral antibacterial drug, and ibuprofen Contraindication Patients should avoid pivmecillinam if they have: Severe hypersensitivity to pivmecillinam or other beta-lactam antibiotics Primary or secondary carnitine deficiency caused by inherited disorders of carnitine metabolism and mitochondrial fatty…
